Japanese
Title57Coブレオマイシンによる腫瘍スキャンの臨床経験
Subtitle原著
Authors鈴木豊*, 久田欣一*, 平木辰之助**
Authors(kana)
Organization*金沢大学医学部核医学科, **金沢大学医療技術短期大学部放射線技術科
Journal核医学
Volume11
Number1
Page7-13
Year/Month1974/2
Article原著
Publisher日本核医学会
Abstract「はじめに」悪性腫瘍を陽性像として描画する, いわゆる腫瘍スキャンニングは, Dewey等が131I Antifibrin Antibodyを用いて試みて以来10年の歴史を有し, Tumor Clinicにおける重要性はますます高まりつつあり, 理想的な腫瘍スキャン用RIの開発が待望される. 今回, 我々は, Nouel等, 河野等によって開発された57Co Bleomycinを臨床に使用する機会を得たので, その知見を報告する. 「症例及び方法」昭和47年11月より昭和48年6月までに悪性腫瘍を疑われて金沢大学医学部附属病院に入院した患者35例に, 本検査を施行した. 第一ラジオアイソトープ研究所製57Co Bleomycin 500μCiを各々の患者に静注した. 静注後, 6時間, 24時間にそれぞれシンチフォトを撮影した. 使用装置は, Nuclear Chicago社製Pho Gamma III型シンチカメラで, 4,000ホール平行コリメーターを用いた.
Practice臨床医学：一般
Keywords
English
TitleClinical Evaluation of the Tumor Scanning with 57Co Bleomycin
SubtitleOriginal
AuthorsYutaka SUZUKI*, Kinichi HISADA*, Tatsunosuke HIRAKI**
Authors(kana)
Organization*Department of Nuclear Medicine, School of Medicine, Kanazawa University, **Department of Radiological Technology, School of Paramedicine, Kanazawa University
JournalThe Japanese Journal of nuclear medicine
Volume11
Number1
Page7-13
Year/Month1974/2
ArticleOriginal article
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract[Summary]In 1963, Dewey et al. first described the possibility of the tumor scanning with 1311 antifibrin antibody. Since then many tumor scanning agents have been reported, however, ideal agent has not been discovered yet. 57Co Bleomycin was introduced to tumor scanning by Nouel et al. in early 1972. The purpose of this paper is to describe our clinical experience with 57Co Bleomycin and discuss its clinical usefulness. Since last November tumor scanning with 57Co Bleomycin was performed for 35 selected patients in our clinic. Five hundred micro curie of 57Co Bleomycin was injected intravenously and two scintiphotos were taken at 6 hours and 24 hours after injection with a gamma camera. No patient had an untowared reaction to the radiopharmaceutical. Confirmed diagnosis was obtained in 27 0ut of 35 patients. Scintiphotos were positive in 15 out of 23 patients with malignant tumor (66%). This result is somewhat inferior to that of 169 Yb citrate and 67Ga citrate. In lung cancer, positive rate was slightly higher i. e. 9 out of 12 cases (75%) and the best result was obtained in squamous cell type lung cancer : 4 out of 5 cases (80%). In laryngeal cancer, however, only one of 3 cases did show positive scan. There was no false positive case in 4 benign lesions. It is well known that Bleomycin has strong therapeutic effect to the squamous cell carcinoma, so it may be an interesting subject whether 57Co Bleomycin has also specific affinity to the squamous cell carcinoma or not. Unfortunately we could not get any answer to this question from this study and we should do further study for this purpose. 57Co Bleomycin disappears rapidly from blood and is excreted mainly through the kidneys, so high tumor / blood ratio is aquired in a short time after injection. This might be the best characteristic of this pharmaceutical. There is no specific organ to which 57Co Bleomycin has special affinity other than kidneys, so it is easier to find the area of abnormal activity. Sometimes this characteristic, however, makes difficult to get information of anatomical site of the lesion. 57Co has ideal energy γ rays for scanning, but its 270 days physical half life might be too long. Since 57Co Bleomycin is excreted rapidly, there might be no problem in radiation dose to the patient, however, many problems in disposal of patients wastes. Long physical half life may restrict the routine use of this radiopharmaceutical in tumor clinic. 57Co Bleomycin has many good properties, so this should be used in selected patients adjunct to other diagnostic study.
PracticeClinical medicine
Keywords

【全文PDF】